Top-News

BioLineRX ADR News

Keine aktuellen Kursdaten verfügbar
WKN: A1JHLB
ISIN: US09071M1062
Typ: Aktie

BioLineRX ADR News

16.06.22 - PR Newswire
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer PR Newswire
11.05.22 - PR Newswire
BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire
05.05.22 - PR Newswire
BioLineRx to Report First Quarter 2022 Results on May 11, 2022
BioLineRx to Report First Quarter 2022 Results on May 11, 2022 PR Newswire
16.03.22 - PR Newswire
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update
BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ...
10.03.22 - PR Newswire
BioLineRx to Report 2021 Annual Results on March 16, 2022
BioLineRx to Report 2021 Annual Results on March 16, 2022 Management to hold a conference call at 10:00 a.m. EST PR Newswire
03.03.22 - PR Newswire
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization - Results ...
24.01.22 - PR Newswire
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors - Initial results ...
18.01.22 - PR Newswire
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients - NDA submission on track for ...
17.12.21 - PR Newswire
Thinking about buying stock in Spruce Biosciences, Bottomline Technologies, BioLine RX, Obseva SA, or Genfit SA?
Thinking about buying stock in Spruce Biosciences, Bottomline Technologies, BioLine RX, Obseva SA, or Genfit SA? PR Newswire
17.12.21 - PR Newswire
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition - Presentation highlighted ...
15.12.21 - PR Newswire
BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)
BioLineRx Announces Formation of Immuno-​Oncology Scientific Advisory Board (SAB) SAB will provide insight and guidance on the Company's immuno-​oncology activities and is ...
18.11.21 - PR Newswire
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update PR Newswire
12.11.21 - PR Newswire
BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
BioLineRx to Report Third Quarter 2021 Results on November 18, 2021 Management to hold a conference call at 10:00 a.m. EST PR Newswire
04.11.21 - PR Newswire
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition - Oral presentation ...
13.10.21 - PR Newswire
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization - Results demonstrate ...
18.08.21 - PR Newswire
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company actively preparing for an NDA submission for Motixafortide in stem cell ...
06.07.21 - PR Newswire
Thinking about buying stock in Exela Technologies, Larimar Therapeutics, Marin Software, Provention Bio, or BioLineRx?
Thinking about buying stock in Exela Technologies, Larimar Therapeutics, Marin Software, Provention Bio, or BioLineRx? PR Newswire
01.07.21 - PR Newswire
Thinking about buying stock in Bridgeline Digital, Seelos Therapeutics, Vistagen Therapeutics, BioLineRx, or Entera Bio?
Thinking about buying stock in Bridgeline Digital, Seelos Therapeutics, Vistagen Therapeutics, BioLineRx, or Entera Bio? PR Newswire
26.05.21 - PR Newswire
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update - Phase 3 GENESIS study in stem-cell mobilization (SCM) demonstrated highly statistically ...
20.05.21 - PR Newswire
BioLineRx to Report First Quarter 2021 Results on May 26, 2021
BioLineRx to Report First Quarter 2021 Results on May 26, 2021 Management to hold a conference call at 10:00 a.m. EDT PR Newswire

Newssuche

Videos

newspaper
09:30 Uhr
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »